In Vivo Efficacy and Tolerability of Artesunate-Azithromycin for the Treatment of Falciparum Malaria in Vietnam

Am J Trop Med Hyg. 2016 Jul 6;95(1):164-7. doi: 10.4269/ajtmh.16-0144. Epub 2016 May 23.

Abstract

Safe and effective antimalarial drugs are required for the treatment of pregnant women. We report a 3-day regimen of artesunate (4 mg/kg/day)-azithromycin (25 mg/kg/day) (ASAZ) to be efficacious (polymerase chain reaction-corrected cure rate of 96.7%) and well tolerated in the treatment of Plasmodium falciparum malaria in children (N = 11) and adults (N = 19), in Vietnam in 2010. In comparison, the cure rate for artesunate (4 mg/kg on day 0, 2 mg/kg on days 1-6) was 90.0% in children (N = 7) and adults (N = 23). Because azithromycin is considered safe in pregnancy, our findings provide further evidence that ASAZ should be evaluated for the treatment of pregnant women with malaria.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antimalarials / therapeutic use*
  • Artemisinins / therapeutic use*
  • Artesunate
  • Azithromycin / therapeutic use*
  • Child
  • Child, Preschool
  • Drug Combinations
  • Drug Resistance*
  • Female
  • Humans
  • Malaria, Falciparum / drug therapy*
  • Male
  • Middle Aged
  • Pilot Projects
  • Plasmodium falciparum / drug effects
  • Pregnancy
  • Vietnam
  • Young Adult

Substances

  • Antimalarials
  • Artemisinins
  • Drug Combinations
  • Artesunate
  • Azithromycin